PDF(Sci-hub)
Abstract：
Erlotinib is one of the most widely used tyrosine kinase inhibitor targeting human epidermal growth factor receptor. Since its introduction, it has revolutionized the treatment of advanced non-small cell lung cancer. Skin rashes and diarrhea are the most often reported side effects of erlotinib however it is also associated with interstitial pneumonitis or interstitial lung disease, which often turns out to be fatal complication of using this medicine. Though reported scarcely in the western world, the association of interstitial lung disease with epidermal growth factor receptor has attracted a lot of attention in the recent times. Various researches working with murine models of bleomycin-induced pulmonary fibrosis have found a pro and con role of the receptor in development of the interstitial lung disease. We present the case of a patient diagnosed with stage IV adenocarcinoma of the lung with metastasis to brain. He was found to be positive for the human epidermal growth factor mutation and was hence started on erlotinib. Within a few weeks of starting the medicine the patient was admitted with diarrhea. During the course of this admission he developed acute shortness of breath diagnosed as interstitial pneumonitis. The purpose of this case report is to review the literature associated with erlotinib induced interstitial pneumonitis and make the practicing oncologists aware of this rare yet fatal complication of erlotinib. Here we will also review literature, pertaining to the role of epidermal growth factor receptor in development of interstitial lung disease.
摘要：
厄洛替尼是最广泛使用的靶向人表皮生长因子受体的酪氨酸激酶抑制剂之一。自推出以来,它彻底改变了晚期非小细胞肺癌的治疗方法。皮疹和腹泻是厄洛替尼最常报道的副作用，但它也与间质性肺炎或间质性肺病有关。这通常是使用这种药物的致命并发症。尽管在西方世界几乎没有报道，近年来，间质性肺病与表皮生长因子受体的关系引起了人们的广泛关注。与博来霉素诱导的肺纤维化的鼠模型一起工作的各种研究已经发现了该受体在间质性肺病的发展中的作用和作用。我们介绍了一名诊断为IV期肺腺癌并转移至脑的患者的情况。发现他对人表皮生长因子突变呈阳性，因此开始服用埃罗替尼。在开始用药的几周内，患者因腹泻入院。在入院过程中，他出现了急性呼吸急促，被诊断为间质性肺炎。该病例报告的目的是回顾与厄洛替尼引起的间质性肺炎相关的文献，并使执业肿瘤学家意识到厄洛替尼的这种罕见但致命的并发症。在这里，我们还将回顾文献，表皮生长因子受体在间质性肺疾病发展中的作用。
